Pharmacological inhibition of acetylcholinesterase improves the locomotion defective phenotype of a SCA3 C. elegans model.

Pohl, Franziska; Lindsay-McGee, Victoria; Kong Thoo Lin, Paul; Maciel, Patricia; Teixeira-Castro, Andreia

Abstract

Inhibition of acetylcholinesterase (AChE) is a common used treatment option for Alzheimer's disease. However, there has been limited research on the potential use of AChE inhibitors for the treatment of Machado-Joseph disease (MJD)/Spinocerebellar Ataxia 3 (SCA3), in spite of the positive results using AChE inhibitors in patients with other inherited ataxias. MJD/SCA3, the most common form of dominant Spinocerebellar Ataxia worldwide, is caused by an expansion of the polyglutamine tract within the ataxin-3 protein, and is characterized by motor impairments. Our study shows that administration of the AChE inhibitor neostigmine is beneficial in treating the locomotion defective phenotype of a SCA3/MJD model of C. elegans and highlights the potential contribution of AChE enzymes to mutant ataxin-3-mediated toxicity.

Citation

POHL, F., LINDSAY-MCGEE, V., KONG THOO LIN, P., MACIEL, P. and TEIXEIRA-CASTRO, A. 2024. Pharmacological inhibition of acetylcholinesterase improves the locomotion defective phenotype of a SCA3 C. elegans model. microPublication biology [online], 2024(2), 001086. Available from: https://doi.org/10.17912/micropub.biology.001086

• Journal Article Type: Article
• Acceptance Date: Feb 2, 2024
• Online Publication Date: Feb 6, 2024
• Publication Date: Feb 29, 2024
• Deposit Date: Feb 12, 2024
• Publicly Available Date: Feb 12, 2024
• Journal: microPublication biology
• Electronic ISSN: 2578-9430
• Publisher: Caltech Library
• Peer Reviewed: Peer Reviewed
• Volume: 2024
• Issue: 2
• Article Number: 001086
• Pages: 10.17912/micropub.biology.001086
• DOI: https://doi.org/10.17912/micropub.biology.001086
• Keywords: Alzheimer's disease; Treatments; AChE inhibitors
• Public URL: https://rgu-repository.worktribe.com/output/2242614